Cargando…
Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781510/ https://www.ncbi.nlm.nih.gov/pubmed/33408024 http://dx.doi.org/10.1016/j.ijantimicag.2020.106171 |
| _version_ | 1783631691673239552 |
|---|---|
| author | Saad, Mohamed O |
| author_facet | Saad, Mohamed O |
| author_sort | Saad, Mohamed O |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7781510 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd and International Society of Antimicrobial Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77815102021-01-05 Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” Saad, Mohamed O Int J Antimicrob Agents Letter to the Editor Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021-01 2021-01-04 /pmc/articles/PMC7781510/ /pubmed/33408024 http://dx.doi.org/10.1016/j.ijantimicag.2020.106171 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Saad, Mohamed O Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
| title | Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
| title_full | Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
| title_fullStr | Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
| title_full_unstemmed | Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
| title_short | Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” |
| title_sort | letter to the editor about “hydroxychloroquine and azithromycin as a treatment of covid-19: results of an open-label non-randomized clinical trial” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781510/ https://www.ncbi.nlm.nih.gov/pubmed/33408024 http://dx.doi.org/10.1016/j.ijantimicag.2020.106171 |
| work_keys_str_mv | AT saadmohamedo lettertotheeditorabouthydroxychloroquineandazithromycinasatreatmentofcovid19resultsofanopenlabelnonrandomizedclinicaltrial |